radioiodine combination therapy (Johns Hopkins University)

N/A

Report date: 2025/03/19 18:27:18
NME

Base Information

Drug Nameradioiodine combination therapy (Johns Hopkins University)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugsRadiation-emitting products > Radioactive therapeutic agent
Mechanisms of ActionProto-oncogene proteins c-akt inhibitorsMitogen-activated protein kinase inhibitorsPI3-kinase class I inhibitors
TargetsProto-oncogene proteins c-aktPI3-kinase class IMitogen-activated protein kinase
Therapy Area/IndicationsThyroid NeoplasmsMelanoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsYes
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesJohns Hopkins University
China Registration ClassN/A

Develop Information

Active CompaniesJohns Hopkins Technology VenturesJohns Hopkins University
Inactive CompaniesN/A
Active IndicationsThyroid NeoplasmsMelanoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A